



S. Rahima Benhabbour, MSc. Ph.D.

Associate Professor

Lampe Joint Department of Biomedical Engineering, UNC-NCSU

Adjunct Associate Professor

**UNC Eshelman School of Pharmacy, Division of Pharmacoengineering and
Molecular Pharmaceutics**

Founder & Director, Anelleo, Inc. (AnelleO)

Bio. Dr. Benhabbour is an Associate Professor in the UNC-NCSU Joint Department of Biomedical Engineering. Her Lab (<https://benhabbour.web.unc.edu/>) focuses on harnessing innovative engineering and chemistry tools to develop the next generation drug delivery technologies for disease treatment and prevention. Dr. Benhabbour is inventor in 4 patents and 6 patent applications, and has received multiple awards and honors including ranking in the top 5% of UNC PIs for NIH funding in 2024-2025, the 2025 CRS Women in Science Award, the 2025 Outstanding Global Engagement Award Finalist by the NCSU Office of Global Engagement, the 2024 BME Outstanding Faculty Research Award, the Alexander R. Matzuk Award, the CRS Member of the Year Award, the CRS FG Young Investigator Award, the David Sokal Innovation Award, the 2023 BME Faculty Research Award, the Eshelman Institute for Innovation Award and many more. She is also the Founder & Director of Anelleo, Inc. (<https://anelleo.com/>), a UNC spinoff company pioneering an innovative 3D printed intravaginal ring platform technology for unmet women's health indications. Her development of highly translational drug delivery technologies has been highlighted through multiple publications in high-impact scientific journals (4 papers published in Nature Communications, Nature Reviews Bioengineering, Biomaterials) and with her latest paper surrounding an innovative technology (PCT/US22/35713) which was featured among the Editors' Highlights pages in Nature Communications, which aims to showcase the 50 best papers recently published in an area (<https://www.nature.com/ncomms/editorshighlights#physical>). This work was also nominated for the CDC's 2024 Charles C. Shepard Science Award. The Shepard Awards recognize excellence in scientific achievement by CDC and ATSDR authors of outstanding scientific papers. Dr. Benhabbour received over \$20M in funding from NIH-NIAID & NIH-NCI R01 and R61 mechanisms, the Gates Foundation, Merck, CONRAD, MCI, CDC, USAID, and UNC to advance and translated her technologies to human studies and make significant impact on women's health globally.